GlassScriptPhysician profile
Rohit Aloor
NPI 1699271262
$1,562.39
in general payments reported to CMS, 2019-2025
12 companies · $608 in 2025
The $608 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.57 · 2023: $236 · 2024: $688 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $369.88 | 2023-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $256.78 | 2023-2025 | Jynarque |
| Ardelyx, INC. | $173.40 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $138.44 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $120.62 | 2023-2024 | Rayaldee |
| Novo Nordisk INC | $118.13 | 2024-2025 | Ozempic, Wegovy |
| Mallinckrodt Hospital Products INC. | $114.01 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $101.02 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $56.77 | 2024-2025 | Farxiga |
| Fresenius USA Marketing, INC. | $50.30 | 2022-2024 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.76 | 2023-2024 | Jardiance |
| Veloxis Pharmaceuticals, INC. | $25.28 | 2025 | Envarsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Aloor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.